Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Mohammad AlkhalilVladimír DžavíkDeepak L BhattRoxana MehranShamir R MehtaPublished in: Current cardiology reports (2022)
inhibitors in stable patients. The duration of DAPT should be tailored to individual patient ischemic and bleeding risks. New strategies, such as early aspirin discontinuation, are promising to reduce bleeding risk without increase in ischemic risk.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- patients undergoing
- st segment elevation myocardial infarction
- acute myocardial infarction
- atrial fibrillation
- st elevation myocardial infarction
- end stage renal disease
- coronary artery disease
- coronary artery bypass grafting
- newly diagnosed
- chronic kidney disease
- ejection fraction
- ischemia reperfusion injury
- low dose
- coronary artery bypass
- peritoneal dialysis
- cardiovascular disease
- oxidative stress
- human health
- patient reported